160 related articles for article (PubMed ID: 11083540)
1. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging of musculoskeletal tumors in the shoulder girdle.
Suzuki H; Watanabe H; Shinozaki T; Yanagawa T; Suzuki R; Takagishi K
J Shoulder Elbow Surg; 2004; 13(6):635-47. PubMed ID: 15570232
[TBL] [Abstract][Full Text] [Related]
3. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.
Miyakubo M; Oriuchi N; Tsushima Y; Higuchi T; Koyama K; Arai K; Paudyal B; Iida Y; Hanaoka H; Ishikita T; Nakasone Y; Negishi A; Mogi K; Endo K
Ann Nucl Med; 2007 Feb; 21(2):129-35. PubMed ID: 17424980
[TBL] [Abstract][Full Text] [Related]
5. Schwannoma of the extremities: the role of PET in preoperative planning.
Ahmed AR; Watanabe H; Aoki J; Shinozaki T; Takagishi K
Eur J Nucl Med; 2001 Oct; 28(10):1541-51. PubMed ID: 11685498
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
Kaira K; Oriuchi N; Otani Y; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Endo K; Mori M
Chest; 2007 Apr; 131(4):1019-27. PubMed ID: 17426205
[TBL] [Abstract][Full Text] [Related]
7. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
8. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
[TBL] [Abstract][Full Text] [Related]
9. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma.
Suzuki R; Watanabe H; Yanagawa T; Sato J; Shinozaki T; Suzuki H; Endo K; Takagishi K
Ann Nucl Med; 2005 Dec; 19(8):661-70. PubMed ID: 16444991
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 3T diffusion-weighted MRI and
Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hemangioma by positron emission tomography: role in a multimodality approach.
Hatayama K; Watanabe H; Ahmed AR; Yanagawa T; Shinozaki T; Oriuchi N; Aoki J; Takeuchi K; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(1):70-7. PubMed ID: 12544246
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
Garcia R; Kim EE; Wong FC; Korkmaz M; Wong WH; Yang DJ; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1476-9. PubMed ID: 8790197
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study.
Tian M; Zhang H; Endo K
J Biomed Biotechnol; 2011; 2011():807929. PubMed ID: 21738405
[TBL] [Abstract][Full Text] [Related]
14. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
15. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
[TBL] [Abstract][Full Text] [Related]
16. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
17. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.
Bader JB; Samnick S; Moringlane JR; Feiden W; Schaefer A; Kremp S; Kirsch CM
Eur J Nucl Med; 1999 Feb; 26(2):144-51. PubMed ID: 9933348
[TBL] [Abstract][Full Text] [Related]
19. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]